{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T08:15:34Z","timestamp":1771229734584,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001823","name":"ministerstvo \u0161kolstv\u00ed, ml\u00e1de\u017ee a t\u011blov\u00fdchovy","doi-asserted-by":"publisher","award":["NU21-03-00611"],"award-info":[{"award-number":["NU21-03-00611"]}],"id":[{"id":"10.13039\/501100001823","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s00277-022-04759-1","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T16:04:23Z","timestamp":1642781063000},"page":"789-798","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical value of ALK and CD30 expression in mature systemic T cell lymphomas: analysis from the Czech Lymphoma Study Group database (NIHIL)"],"prefix":"10.1007","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2647-7769","authenticated-orcid":false,"given":"A.","family":"Janikova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Michalka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Chloupkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Kopalova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Campr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Kamaradova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Kren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Belada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Benesova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Dlouha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Klener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Proch\u00e1zka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Mocikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Duras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Trneny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"key":"4759_CR1","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1111\/bjh.13202","volume":"168","author":"AM Petrich","year":"2015","unstructured":"Petrich AM, Helenowski IB, Bryan LJ et al (2015) Factors predicting survival in peripheral T-cell lymphoma in the USA: a population-based analysis of 8802 patients in the modern era. British Journal of Heamatology 168:708\u2013718","journal-title":"British Journal of Heamatology"},{"issue":"10","key":"4759_CR2","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","volume":"124","author":"F Ellin","year":"2014","unstructured":"Ellin F, Landstr\u00f6m J, Jerkeman M, Relander T (2014) Real-word data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood 124(10):1570\u20131577","journal-title":"Blood"},{"key":"4759_CR3","doi-asserted-by":"crossref","unstructured":"Pedersen MB, Hamilton-Dutoit SJ, Bendix K et al (2015) Evaluation of clinical trial eligibility and prognostic indices in a population-based cohort of systemic peripheral T-cell lymphomas from the Danish Lymphoma Registry. Hematological Oncology\u00a0 33:120\u2013128","DOI":"10.1002\/hon.2153"},{"issue":"8","key":"4759_CR4","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1007\/s00277-019-03694-y","volume":"98","author":"A Janikova","year":"2019","unstructured":"Janikova A, Chloupkova R, Campr V et al (2019) First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients. Ann Hematol 98(8):1961\u20131972","journal-title":"Ann Hematol"},{"key":"4759_CR5","doi-asserted-by":"publisher","unstructured":"Gambacorti Passerini C, Farina F, Stasia A et al ( 2014) Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients. J Natl Cancer Inst 106(2):djt378.\u00a0https:\/\/doi.org\/10.1093\/jnci\/djt378","DOI":"10.1093\/jnci\/djt378"},{"issue":"28","key":"4759_CR6","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1200\/JCO.2017.73.4830","volume":"35","author":"YP Moss\u00e9","year":"2017","unstructured":"Moss\u00e9 YP, Voss SD, Lim MS et al (2017) Targeting with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a Children\u2019s Oncology Study Group. J Clin Oncol 35(28):3215\u20133221","journal-title":"J Clin Oncol"},{"key":"4759_CR7","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","volume":"123","author":"SM Horwitz","year":"2014","unstructured":"Horwitz SM, Advani RH, Bartlett NL et al (2014) Objective responses in relapses T-cell lymphomas with single-agent brentuximab vedotin. Blood 123:3095\u20133100","journal-title":"Blood"},{"issue":"5151","key":"4759_CR8","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1126\/science.8122112","volume":"263","author":"SW Morris","year":"1994","unstructured":"Morris SW, Kirstein MN, Valentine MB et al (1994) Fusion of kinase gene, ALK, to a nuclear protein gene, NPM, in non-Hodgkin\u00b4s lymphoma. Science 263(5151):1281\u20131284","journal-title":"Science"},{"key":"4759_CR9","doi-asserted-by":"publisher","unstructured":"Lobello C, Bikos V, Janikova A, Pospisilova S ( 2018) The role of oncogenic tyrosine kinase NPM-ALK in genomic instability. Cancers 10:64. https:\/\/doi.org\/10.3390\/cancers10030064","DOI":"10.3390\/cancers10030064"},{"key":"4759_CR10","doi-asserted-by":"publisher","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","volume":"111","author":"KJ Savage","year":"2008","unstructured":"Savage KJ, Harris NL, Vose JM et al (2008) ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 111:5496\u20135504","journal-title":"Blood"},{"key":"4759_CR11","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1200\/JCO.2012.42.2345","volume":"30","author":"D Sibon","year":"2012","unstructured":"Sibon D, Fournier M, Bri\u00e9re J et al (2012) Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d\u00b4\u00c9tude des Lymphomes de l\u00b4Adulte Trials. J Clin Oncol 30:3939\u20133946","journal-title":"J Clin Oncol"},{"issue":"3","key":"4759_CR12","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/0092-8674(92)90180-K","volume":"68","author":"H D\u00fcrkop","year":"1992","unstructured":"D\u00fcrkop H, Latza U, Hummel M et al (1992) Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin\u00b4s disease. Cell 68(3):421\u2013427","journal-title":"Cell"},{"key":"4759_CR13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1440-1827.2007.02195.x","volume":"58","author":"K Karube","year":"2008","unstructured":"Karube K, Aoki R, Nomura Y et al (2008) Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: analysis of 490 cases. Pathol Int 58:89\u201397","journal-title":"Pathol Int"},{"issue":"e111","key":"4759_CR14","first-page":"1","volume":"3","author":"SM Rodriguez-Pinilla","year":"2013","unstructured":"Rodriguez-Pinilla SM, Sanchez ME, Rodriguez J et al (2013) Loss of TCR-beta F1 and\/or EZRIN expression is associated with unfavorable prognosis in nodal peripheral T-cell lymphomas. Blood Cancer J 3(e111):1\u20138","journal-title":"Blood Cancer J"},{"key":"4759_CR15","doi-asserted-by":"crossref","unstructured":"Onaindia A, Martinez N, Montes-Moreno S et al ( 2016) CD30 expression by B and T cells. A frequent finding in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma-not otherwise specified. Am J Surg Pathol 40:378\u201385","DOI":"10.1097\/PAS.0000000000000571"},{"issue":"1","key":"4759_CR16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/annonc\/mdj030","volume":"17","author":"KJ Savage","year":"2006","unstructured":"Savage KJ, Al-Rajhi N, Voss N et al (2006) Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol 17(1):123\u2013130","journal-title":"Ann Oncol"},{"issue":"14","key":"4759_CR17","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1182\/blood-2012-10-461848","volume":"121","author":"S Hu","year":"2013","unstructured":"Hu S, Xu-Monette Z, Balasubramanyam A et al (2013) CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood 121(14):2715\u20132724","journal-title":"Blood"},{"issue":"8","key":"4759_CR18","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.3324\/haematol.2012.081935","volume":"98","author":"B Bisig","year":"2013","unstructured":"Bisig B, de Reyni\u00e9s A, Bonnet Ch et al (2013) CD-30 positive T-cell lymphomas share molecular and phenotypic features. Hematologica 98(8):1250\u20131258","journal-title":"Hematologica"},{"issue":"24","key":"4759_CR19","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1200\/JCO.2012.42.5611","volume":"32","author":"PP Piccaluga","year":"2013","unstructured":"Piccaluga PP, Fuligni F, De Leo A et al (2013) Molecular profiling improves classification and prognostication of nodal peripheral T-cell lymphomas: results of a phase III diagnostic accuracy study. J Clin Oncol 32(24):3019\u20133025","journal-title":"J Clin Oncol"},{"key":"4759_CR20","first-page":"1860","volume":"31","author":"PP Carbone","year":"1971","unstructured":"Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M (1971) Report of the Committee on Non-Hodgkin\u2019s Disease Staging Classification. Cancer Res 31:1860\u20131861","journal-title":"Cancer Res"},{"key":"4759_CR21","first-page":"146","volume":"23","author":"A Sykorova","year":"2010","unstructured":"Sykorova A, Belada D, Smolej L et al (2010) Staging of non-Hodgkin\u2019s lymphoma \u2013recommendations of the Czech Lymphoma Study Group. Klin Onkol 23:146\u2013154","journal-title":"Klin Onkol"},{"key":"4759_CR22","doi-asserted-by":"crossref","unstructured":"Cheson BD, Horning SJ, Coiffier B et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol\u00a017:1244","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"4759_CR23","doi-asserted-by":"crossref","unstructured":"Cheson BD, Pfistner B, Juweid ME et al (2007) International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579\u201386","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"4759_CR24","unstructured":"Swerdlow SH, Campo E, Harris NL et al (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. International Agency for Research on Cancer (IARC); 4th Edition, Lyon\u00a0"},{"issue":"20","key":"4759_CR25","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375\u20132390","journal-title":"Blood"},{"key":"4759_CR26","doi-asserted-by":"crossref","unstructured":"Horwitz S, O\u00b4Connor OA, Pro B et al (2019) Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global double-blind, randomized, phase 3 trial. Lancet 393:229\u201340","DOI":"10.1016\/S0140-6736(18)32984-2"},{"key":"4759_CR27","doi-asserted-by":"crossref","unstructured":"Marchi E, O\u00b4Connor OA (2020) The rapidly changing landscape in mature T-cell lymphoma (MTCL) biology and management. CA Cancer J Clin 70:47\u201370","DOI":"10.3322\/caac.21589"},{"key":"4759_CR28","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ejca.2017.06.026","volume":"83","author":"A Morel","year":"2017","unstructured":"Morel A, Bri\u00e8re J, Lamant L et al (2017) Long-term outcomes of adults with first-relapsed\/refractory systemic anaplastic large-cell lymphoma in the pre-brentuximab vedotin era: A LYSA\/SFGM-TC study. Eur J Cancer 83:146\u2013153","journal-title":"Eur J Cancer"},{"issue":"5","key":"4759_CR29","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1111\/j.1365-2141.2005.05808.x","volume":"131","author":"SL Perkins","year":"2005","unstructured":"Perkins SL, Pickering D, Lowe EJ et al (2005) Childhood anaplastic large cell lymphoma has a high incidence of ALK gene rearrangement as determined by immunohistochemical staining and fluorescent in situ hybridisation: a genetic and pathological correlation. Br J Haematol 131(5):624\u2013627","journal-title":"Br J Haematol"},{"issue":"10","key":"4759_CR30","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.1111\/cas.14177","volume":"110","author":"X Zhou","year":"2019","unstructured":"Zhou X, Shou J, Sheng J et al (2019) Molecular and clinical analysis of Chinese patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer. Cancer Sci 110(10):3382\u20133390","journal-title":"Cancer Sci"},{"key":"4759_CR31","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/bjh.16741","volume":"192","author":"SM Rodriguez-Pinilla","year":"2021","unstructured":"Rodriguez-Pinilla SM, Domingo-Domenech E, Climent F et al (2021) Clinical and pathological characteristics of peripheral T-cell lymphomas in a Spanish population: a retrospective study. Br J Haematology 192:82\u201399","journal-title":"Br J Haematology"},{"key":"4759_CR32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1080\/17474086.2017.1270202","volume":"10","author":"JMR Pierce","year":"2017","unstructured":"Pierce JMR, Mehta A (2017) Diagnostic, prognostic and therapeutic role of CD30 in lymphoma. Expert Rev Hematol 10:29\u201337","journal-title":"Expert Rev Hematol"},{"key":"4759_CR33","doi-asserted-by":"crossref","unstructured":"Federico M, Bellei M, Marcheselli L et al (2018) Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network. British Journal of Haematology 181:760\u201369","DOI":"10.1111\/bjh.15258"},{"issue":"1","key":"4759_CR34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1080\/1354750X.2019.1691656","volume":"25","author":"MQ Salas","year":"2020","unstructured":"Salas MQ, Climent F, Tapia G et al (2020) Clinicopathologic features and prognostic significance of CD30 expression in de novo diffuse large B-cell lymphoma (DLBCL): results in a homogeneous series from a single institution. Biomarkers 25(1):69\u201375","journal-title":"Biomarkers"},{"issue":"26","key":"4759_CR35","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1182\/blood.2019001821","volume":"134","author":"SK Barta","year":"2019","unstructured":"Barta SK, Gong JZ, Porcu P (2019) Brentuximab vedotin in the treatment of CD30+ PTCL. Blood 134(26):2339\u20132345","journal-title":"Blood"},{"key":"4759_CR36","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1080\/17474086.2021.1955344","volume":"14","author":"K Karube","year":"2021","unstructured":"Karube K, Kakimoto Y, Tonozuka Y, Ohshima K (2021) The expression of CD30 and its clinico-pathologic significance in peripheral T-cell lymphomas. Expert Rev Hematol 14:777\u2013787","journal-title":"Expert Rev Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04759-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-04759-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04759-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,10]],"date-time":"2022-03-10T12:08:01Z","timestamp":1646914081000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-04759-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,21]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["4759"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-04759-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,21]]},"assertion":[{"value":"30 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in the study involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}